Clinical Trials

EuropaColon introduces their booklet on Understanding Clinical Trials in Colorectal Cancer (CRC).

Patient Partner - Identifying the needs of Patient Partnering in Clinical Research

The aim of the project is to identify patients' needs for partnership in clinical trials. The project is a collaboration of the Dutch Genetic Alliance, The European Genetic Alliances Network, The Genetic Interest Group and the European Forum of Good Clinical Practice and covers all disease areas in its objectives. The main aim of the project is to open up dialogue between patient organisations, the pharmaceutical industry and academia on how patient organisations can become more equal partners in clinical trials and clinical research. It is intended that eventually this will lead to practical guidelines on how this can be made possible. The project features an inventory of current best practices, regional and European wide multi-stakeholder workshops and a European wide forum for patient organisations who want to exchange their views on the topic of partnering in clinical trials and research (ENPCR).

More information on the project and opportunities to get involved in its activities can be found on

EuropaColon would like to thank The U.S. National Library of Medicine (NLM) and

Useful links:

For European trials:

European Medicines Agency website:

The MErCuRIC Project

A trial looking at crizotinib, PD-0325901 and binimetinib (MErCuRIC1)

More than half of all bowel cancer patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Bowel cancer, also known as colorectal cancer refers to cancer that starts in the colon (large bowel) or back passage (rectum). Increased understanding of cancer biology, coupled with the implementation of “omics”-based approaches, has revealed that cancer must be considered a heterogeneous disease. Historically, “one-size-fits-all” approaches have been standard practice in bowel cancer treatment, but with the increased understanding of the molecular/genetic heterogeneity of bowel cancer, it is clear that novel treatments must be developed and tested in selected subgroups to maximize the benefit of these new developments.

MErCuRIC is a multicentre phase Ib/II clinical trial which will assess a novel therapeutic strategy (combined treatment of a MEK inhibitor MEK-162 with a MET inhibitor PF-02341066) to combat metastasis, improve survival and change current clinical practice for CRC patients with KRAS mutant (MT) and KRAS wild-type (WT) (with aberrant c-MET) tumours. The consortium will go beyond the current state-of-the-art by (i) employing a novel treatment strategy targeting the biology of the disease and by (ii) using next-generation sequencing (NGS) and ‘xenopatients’ to identify CRC patient subgroups who will maximally benefit from this novel treatment strategy.

CLICK HERE to find out more.

More information from Cancer Research UK.

Registration No: 5314195 Registered Office: 92 Palatine Road, London N16 8ST.